206 related articles for article (PubMed ID: 20188141)
1. F104S c-Mpl responds to a transmembrane domain-binding thrombopoietin receptor agonist: proof of concept that selected receptor mutations in congenital amegakaryocytic thrombocytopenia can be stimulated with alternative thrombopoietic agents.
Fox NE; Lim J; Chen R; Geddis AE
Exp Hematol; 2010 May; 38(5):384-91. PubMed ID: 20188141
[TBL] [Abstract][Full Text] [Related]
2. Functional characterization of c-Mpl ectodomain mutations that underlie congenital amegakaryocytic thrombocytopenia.
Varghese LN; Zhang JG; Young SN; Willson TA; Alexander WS; Nicola NA; Babon JJ; Murphy JM
Growth Factors; 2014 Feb; 32(1):18-26. PubMed ID: 24438083
[TBL] [Abstract][Full Text] [Related]
3. Compound heterozygous c-Mpl mutations in a child with congenital amegakaryocytic thrombocytopenia: functional characterization and a review of the literature.
Fox NE; Chen R; Hitchcock I; Keates-Baleeiro J; Frangoul H; Geddis AE
Exp Hematol; 2009 Apr; 37(4):495-503. PubMed ID: 19302922
[TBL] [Abstract][Full Text] [Related]
4. The thrombopoietin receptor P106L mutation functionally separates receptor signaling activity from thrombopoietin homeostasis.
Stockklausner C; Klotter AC; Dickemann N; Kuhlee IN; Duffert CM; Kerber C; Gehring NH; Kulozik AE
Blood; 2015 Feb; 125(7):1159-69. PubMed ID: 25538044
[TBL] [Abstract][Full Text] [Related]
5. Functional analysis of single amino-acid mutations in the thrombopoietin-receptor Mpl underlying congenital amegakaryocytic thrombocytopenia.
Tijssen MR; di Summa F; van den Oudenrijn S; Zwaginga JJ; van der Schoot CE; Voermans C; de Haas M
Br J Haematol; 2008 Jun; 141(6):808-13. PubMed ID: 18422784
[TBL] [Abstract][Full Text] [Related]
6. Dissecting the thrombopoietin receptor: functional elements of the Mpl cytoplasmic domain.
Drachman JG; Kaushansky K
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2350-5. PubMed ID: 9122198
[TBL] [Abstract][Full Text] [Related]
7. Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim.
Pecci A; Ragab I; Bozzi V; De Rocco D; Barozzi S; Giangregorio T; Ali H; Melazzini F; Sallam M; Alfano C; Pastore A; Balduini CL; Savoia A
EMBO Mol Med; 2018 Jan; 10(1):63-75. PubMed ID: 29191945
[TBL] [Abstract][Full Text] [Related]
8. A novel and simple hollow-fiber assay for in vivo evaluation of nonpeptidyl thrombopoietin receptor agonists.
Xie CY; Xu YP; Zhao HB; Lou LG
Exp Hematol; 2012 May; 40(5):386-92. PubMed ID: 22269115
[TBL] [Abstract][Full Text] [Related]
9. Severe Clinical Course in a Patient with Congenital Amegakaryocytic Thrombocytopenia Due to a Missense Mutation of the c-MPL Gene.
Ok Bozkaya İ; Yaralı N; Işık P; Ünsal Saç R; Tavil B; Tunç B
Turk J Haematol; 2015 Jun; 32(2):172-4. PubMed ID: 26316487
[TBL] [Abstract][Full Text] [Related]
10. [Congenital amegakaryocytic thrombocytopenia in a 12 year old boy with no signs of pancytopenia: molecular analysis].
Bastida Eizaguirre M; Pereda Vicandi A; Pujana Zaldegui I
An Pediatr (Barc); 2008 Apr; 68(4):353-6. PubMed ID: 18394379
[TBL] [Abstract][Full Text] [Related]
11. Defective response to thrombopoietin and impaired expression of c-mpl mRNA of bone marrow cells in congenital amegakaryocytic thrombocytopenia.
Muraoka K; Ishii E; Tsuji K; Yamamoto S; Yamaguchi H; Hara T; Koga H; Nakahata T; Miyazaki S
Br J Haematol; 1997 Feb; 96(2):287-92. PubMed ID: 9029014
[TBL] [Abstract][Full Text] [Related]
12. The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl.
Drachman JG; Griffin JD; Kaushansky K
J Biol Chem; 1995 Mar; 270(10):4979-82. PubMed ID: 7534285
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of an alternative splice variant of Mpl with a high affinity for TPO and its activation of ERK1/2 signaling.
Wang Q; Sun R; Wu L; Huang J; Wang P; Yuan H; Qiu F; Xu X; Wu D; Yu Y; Liu X; Zhang Q
Int J Biochem Cell Biol; 2013 Dec; 45(12):2852-63. PubMed ID: 24144576
[TBL] [Abstract][Full Text] [Related]
14. Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia.
Shin J; Kim MJ; Quan X; Kim JW; Lee S; Park S; Jeong JY; Yea K
BMC Cancer; 2023 May; 23(1):490. PubMed ID: 37259024
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo expansion of human hematopoietic stem cells by a small-molecule agonist of c-MPL.
Nishino T; Miyaji K; Ishiwata N; Arai K; Yui M; Asai Y; Nakauchi H; Iwama A
Exp Hematol; 2009 Nov; 37(11):1364-1377.e4. PubMed ID: 19744539
[TBL] [Abstract][Full Text] [Related]
16. Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia.
Ihara K; Ishii E; Eguchi M; Takada H; Suminoe A; Good RA; Hara T
Proc Natl Acad Sci U S A; 1999 Mar; 96(6):3132-6. PubMed ID: 10077649
[TBL] [Abstract][Full Text] [Related]
17. Advances in the understanding of congenital amegakaryocytic thrombocytopenia.
Ballmaier M; Germeshausen M
Br J Haematol; 2009 Jun; 146(1):3-16. PubMed ID: 19388932
[TBL] [Abstract][Full Text] [Related]
18. Congenital amegakaryocytic thrombocytopenia: clinical and biological consequences of five novel mutations.
Savoia A; Dufour C; Locatelli F; Noris P; Ambaglio C; Rosti V; Zecca M; Ferrari S; di Bari F; Corcione A; Di Stazio M; Seri M; Balduini CL
Haematologica; 2007 Sep; 92(9):1186-93. PubMed ID: 17666371
[TBL] [Abstract][Full Text] [Related]
19. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia.
Ballmaier M; Germeshausen M; Schulze H; Cherkaoui K; Lang S; Gaudig A; Krukemeier S; Eilers M; Strauss G; Welte K
Blood; 2001 Jan; 97(1):139-46. PubMed ID: 11133753
[TBL] [Abstract][Full Text] [Related]
20. Signaling properties of murine MPL and MPL mutants after stimulation with thrombopoietin and romiplostim.
Rommel MGE; Hoerster K; Milde C; Schenk F; Roser L; Kohlscheen S; Heinz N; Modlich U
Exp Hematol; 2020 May; 85():33-46.e6. PubMed ID: 32417303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
